Francesca Bacchiarri

Francesca Bacchiarri


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
Donatella RaspadoriDonatella Raspadori
Donatella Raspadori
FBFrancesca Bacchiarri
Francesca Bacchiarri
ASAnna Sicuranza
Anna Sicuranza
PPPaola Pacelli
Paola Pacelli
MBMonica Bocchia
Monica Bocchia
Novel drugs have revolutionized multiple myeloma therapy in the last 20 years, with median survival that has doubled to up to 8–10 years. The introduction of therapeutic strategies, such as consolidation and maintenance after autologous stem cell transplants, has also ameliorated clinical results. The goal of modern therapies is becoming not only complete remission, but also the deepest possible remission. In this context, the evaluation of minimal residual disease by techniques such as next-generation sequencing (NGS) and next-generation flow (NGF) is becoming part of all new clinical trials that test drug efficacy. This review focuses on minimal residual disease approaches in clinical trials, with particular attention to real-world practices.

19 November 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
VSVincenzo Sammartano
Vincenzo Sammartano
FBFrancesca Bacchiarri
Francesca Bacchiarri
Donatella RaspadoriDonatella Raspadori
Donatella Raspadori
MBMonica Bocchia
Monica Bocchia

Verified
Journal Article
Open access
PDF file
VSVincenzo Sammartano
Vincenzo Sammartano
EAElisabetta Antonioli
Elisabetta Antonioli
GBGabriele Buda
Gabriele Buda
SCSara Ciofini
Sara Ciofini
VCVeronica Candi
Veronica Candi
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal antibody that targets CD38, a glycoprotein uniformly expressed on human plasma cells. Daratumumab has been utilized in recent years with unprecedented responses in multiple myeloma. In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and improvement in organ function. Here, we report real-life treatment with Daratumumab in 33 AL amyloidosis patients treated within the Regional Tuscan Myeloma network at 5 centers with associated MGUS or SMM (n = 15) or symptomatic MM (n = 18). Patients were treated at relapsed/refractory disease stages (n = 29) with a median of one previous line of therapy or at diagnosis (n = 4). Daratumumab showed good efficacy, representing 60% of good hematological responses and 50% of organ responses in a real-life population of patients with an acceptable toxicity profile.

4 April 2022 in Clinical Case Reports
Verified
Journal Article
Open access
FBFrancesca Bacchiarri
Francesca Bacchiarri
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
NMNicola Mondanelli
Nicola Mondanelli
Stefano LazziStefano Lazzi
Stefano Lazzi
MBMonica Bocchia
Monica Bocchia
Skeletal involvement in CLL is very rare. We present a case of ileum bone lesion during in a patient receiving 5th line of therapy. Despite radiotherapy and salvage therapies, subsequent bone lesions led to a fatal outcome. Further studies on the mechanism by which bone disease develops are currently needed.

5 November 2020 in Blood
Verified
Journal Article
Open access
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
Donatella RaspadoriDonatella Raspadori
Donatella Raspadori
PPPaola Pacelli
Paola Pacelli
EAElisabetta Antonioli
Elisabetta Antonioli
EBElena Bestoso
Elena Bestoso
MBMonica Bocchia
Monica Bocchia
Background. New drugs with or without autologous stem cell transplantation (ASCT) can induce deep CR responses. MRD can be now considered in the response evaluation by the IMWG and many studies propose it as surrogate for survivals. Multiparametric flow cytometric assays have now been replaced by advanced assays that permit to assess simultaneously more than 8 markers in a single tube. In particular, Euro-flow consortium has developed NGF, a novel high sensitive and standardized approach for MM MRD evaluation that is based on the use of 2 single 8-color tubes, containing all the markers needed to distinguish normal vs MM PCs. However, it is necessary to work on fresh samples and to acquire 107 cell/sample, so to have the possibility to evaluate the Limit Of Quantification (LOQ) and the Limit Of Detection (LOD). The LOQ is calculated as 50 clonal plasmacells among 107 nucleated cells; the LOD as 20 clonal plasmacells among 107 nucleated cells. Aim. DART4MM is a single arm, multicenter, prospective study that evaluate Daratumumab effect on MM patients who already achieved VGPR/CR but MRD positive by NGF after a first line therapy (ASCT, VMP) (Gozzetti et al. IMW 2019). The purpose was to analyze 10.000.000 cells for MRD evaluation and reach at least 10-6 level. Patients and Methods. Next generation flow (NGF) is centralized and measured at Siena University Hospital with two 8 colors tubes panel developed by the EuroFlow Consortium (BD OneFLOW Tm PCSTe BD OneFLOW Tm PCD. BD BioSciences) with detection of MRD with a sensitivity (≥ 1 in 105 /10-6). Daratumumab 16 mg/kg administered at weekly intervals for 8 weeks, then every 2 weeks for an additional 8 weeks, will be given to 50 MM patients who achieved a VGPR or more defined as per IMWG criteria and MRD-positivity (by NGF). Daratumumab starts at least 12 weeks from ASCT and at least 4 weeks after VMP. Free light chain (FLC) and CT/PET are evaluated at time 0 and every 6 months. NGF is done on marrow aspirate at time 0, at 2 months and every 6 months for 2 years. Primary endpoint is achievement of MRD negativity at 6 months: if patients are MRD negative after 6 months of therapy, treatment is stopped. Otherwise treatment will continue every 4 weeks up to 2 years. Rapid infusion was allowed from the third dose (cycle 1, day 15) if no serious IRR was seen in the previous infusion (second). The infusion rate was calculated to deliver 20% of the dose over 30 min (200 mL/hr), and then the rate was increased to deliver the remaining 80% over 60 min (450 mL/hr). This resulted in a 90 min estimated infusion time (total volume 550 mL). Results. Recruitment started at the end of December 2018. 70 patients were screened until July 2020 at 5 centers in Italy. At least 10 million cells were analyzed for sensitivity at flow for each sample. 31/70 (44%) resulted MRD positive and eligible. M/F =15/16, median age was 61 (range 48-68).Three patients were excluded from the protocol because of consent withdraw. Previous therapy were single ASCT (21 patients), double ASCT 3 patient, VMP (3 patients), KRD (1 patient). ISS stage was I in 8 patients, II in 9 patients, and III in the other 6 patients. Cytogenetics/FISH analysis at diagnosis was done in 25/28 patients : it was negative for 17p deletion, t(14q) and 1q amplification in 16 patients, 2 had t(4;14) , 5 had t(11;14), 2 had del 17p, 1 del 13q, +11 in 2. Grade 2 reaction (moderate infusion-related reactions) during first daratumumab infusion was seen in 10/28 (35%) patients and promptly resolved with corticosteroids administration and temporary infusion interrumption. More than 200 rapid infusions were given to 16 patients. No serious adverse event was registered. 22/28 (79%) patients completed 8 weeks of treatment (2 months) and evaluated MRD. 17/28 (60%) completed 6 months of therapy. MRD negativity was reached at 6 months in 9/17patients (53%). Interestingly 9/13 (62%) patients treated previously with ASCT were MRD negative (10-6) after 6 months of Dara and stopped treatment. 12 patients reached 12 months of follow up: 2/12 patients are still MRD negative at 10-7 (6 lost MRD negativity). Conclusions. Follow up will continue with marrow evaluation for MRD every 6 months until 2 years. Having at disposition high quality BM samples for MRD evaluation can ameliorate our assays, even to 10-6 or 10-7 and it is crucial to have a good coordination between clinicians and laboratories so to improve the accuracy, sensitivity, and specificity of MM MRD detection in MM patients.

26 March 2026 in British Journal of Haematology
Verified
Journal Article
Open access
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
PPPaola Pacelli
Paola Pacelli
FCFederico Caroni
Federico Caroni
DRDonatella Raspadori
Donatella Raspadori
EBElena Bestoso
Elena Bestoso
MBMonica Bocchia
Monica Bocchia
Summary: Daratumumab is approved for front‐line and relapsed myeloma therapy. Here, we evaluated daratumumab in multiple myeloma patients already in ≥very good partial response but minimal residual disease (MRD) positive by next‐generation flow after first‐line therapy and daratumumab naïve with the potential to eradicate the disease. In this prospective, single‐arm phase 2 trial, we consecutively evaluated 110 eligible patients with newly diagnosed multiple myeloma for positivity at 10 −6 in the bone marrow. Fifty patients were positive and were treated with 6 months of daratumumab. The primary end‐point was at 6 months: MRD‐negative patients stopped treatment, while positive patients continued for a total of 24 months. At the primary end‐point, 15/50 (30%) patients became MRD negative. At 24 months, 11/50 (22%) patients were still MRD negative. At a median follow‐up of 50 months, 29 (58%) patients relapsed. Median progression‐free survival is reached at 45 months, and overall survival is not reached. Achieving at least one‐time MRD negativity was significant (median progression‐free survival of 61 vs. 26 months, p = 0.0009). Of 50 patients, 21 did not progress at a median time of 44 months (range 31–73) and four of the relapsed patients are still in duration of response, not treated yet.